ERBB2 and breast cancer: Furthermore, a phase Ib trial investigated atezolizumab with T-DM1 in HER2-positive early BC (eBC), LABC, or mBC, showing an acceptable safety profile, along with an enhanced adaptive immune response in eBC tumors compared to those with mBC [76].